Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology

Volume: 45, Issue: 5, Pages: 100799 - 100799
Published: Oct 1, 2021
Abstract
Drug delivery to select therapeutic targets for precision oncology has always been a major challenge in oncology. Anti-body drug conjugates (ADC) and radiopharmaceuticals attempt to overcome the major limitations of chemotherapy or mono-clonal antibody therapy as they provide a highly specific means of attacking the vulnerability of the cancer cell. Currently there are over 100 clinical trials in various stages of development with these agents....
Paper Details
Title
Optimizing anti–body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology
Published Date
Oct 1, 2021
Volume
45
Issue
5
Pages
100799 - 100799
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.